Drug Profile
Research programme: cancer therapies - CytoGenix
Alternative Names: Cancer therapies research programme -CytoGenixLatest Information Update: 02 Jun 2010
Price :
$50
*
At a glance
- Originator CytoGenix
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cancer metastases
Most Recent Events
- 23 Jan 2004 Cytogenix and Baylor College of Medicine have entered into an agreement to co-develop a ssDNA expression vector administered via aerosol delivery in the US for metastatic lung cancer
- 23 Jan 2004 Preclinical trials in Cancer metastases in USA (unspecified route)
- 22 Oct 2003 This programme is available for licensing (http://www.cytogenix.com)